Navigation Links
EU5 Nephrologists Report a Stabilization of Phosphate Binder Treatment Prevalence in the Late-Stage CKD and Dialysis Patient Populations
Date:2/5/2013

EXTON, Penn., Feb. 5, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds the following key results, according to a recent BioTrends' report, ChartTrends: Bone and Mineral Metabolism in Chronic Kidney Disease - Non-Dialysis (CKD-ND) and Dialysis, which contains data from 962 EU5 dialysis patient charts and 928 EU5 CKD-ND patient charts:

  • On average, nephrologists in the EU5 countries indicate that they are managing slightly over 100 dialysis patients and over 200 Stage 3 and 4 CKD-ND patients
  • In all countries, the general practitioner is the most common referral source to the nephrologist, accounting for 40-60 percent of all nephrology patient referrals
  • Phosphate binder treatment prevalence in both the dialysis and CKD-ND has remained consistent over time
  • Approximately 73 percent of nephrologists report that they initiate binders when dialysis patients are above the phosphorus level at which the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend, clearly indicating that more education is needed
  • As is the case in the United States market, calcium and non-calcium binders generally split the phosphate binder market. However, Fosrenol (Shire) use is higher in the EU5 compared to the U.S. and as well, use of sevelamer's (Sanofi Renal) powder formulation is higher in the EU5 compared to the U.S.
  • Prevalence of Nutritional Vitamin D treatment in dialysis patients appears to be increasing across both dialysis modalities, with currently over 30 percent of dialysis patients treated in 2012
  • Physicians' choice of Active Vitamin D varies by EU5 country, with U.K. and French physicians choosing alfacalcidol most often in both their dialysis and CKD-ND patients, German and Italian physicians choosing calcitriol most often and Spanish physicians choosing paricalcitol (Abbott's Zemplar) most often
  • Mimpara (Amgen) use in the EU5 countries has remained consistent over time
  • (Logo: http://photos.prnewswire.com/prnh/20130103/MM36805LOGO)

    "While phosphate binder treatment prevalence has remained consistent from the prior year, we are now seeing patient share changes with regards to the brands and formulations, especially as it relates to sevelamer and Fosrenol," said Rob Dubman , BioTrends' Director of Nephrology.

    ChartTrends®: Bone and Mineral Metabolism in Dialysis and CKD-ND (EU5) is a syndicated report series, in which 210 nephrologists provided patient chart data on 962 dialysis patients in the EU5 and 191 nephrologists provided patient chart data on 928 CKD-ND patients in the EU5 in the most recent wave of research to uncover the actual management related to bone and mineral metabolism. Through an in-depth review of patient charts, details such as product dosing and titration, switching, concomitant medications, and a host of laboratory and patient demographic variables help define patient types and identify therapy triggers.

    The study also evaluated referral patterns, co-morbidities, blood transfusions, hospitalizations and a host of other patient demographics and laboratory data. BioTrends is publishing ChartTrends: Bone and Mineral Metabolism in dialysis later this year in the US. Additional ChartTrends reports have been published in China and Latin America (Brazil, Argentina and Mexico).

    About BioTrends Research GroupBioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact us at (610) 321-9400 or www.bio-trends.com.

    About Decision Resources Group
    Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

    All company, brand, or product names contained in this document may be trademarks of their respective holders.For more information, contact:BioTrends Research GroupDecision Resources GroupRob Dubman

    Christopher Comfort781-993-2592

    781-993-2597 rdubman@bio-trends.com

    ccomfort@dresources.com


    '/>"/>
    SOURCE BioTrends Research Group
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Solta Medical to Report Fourth Quarter 2012 Results Release and Host Conference Call on February 19, 2013
    2. Cardinal Health Reports Fiscal 2013 Second-Quarter Results
    3. Luminex Corporation Reports Fourth Quarter And Full Year 2012 Results
    4. InspireMD Reports Results for Period Ended Dec. 31, 2012
    5. Sequenom CMMs MaterniT21 PLUS LDT Now Reporting On Gender-Specific Chromosomal Abnormalities
    6. BRICS NPWT Market and Pressure Relief Devices Industry Analysis in New Research Reports at ReportsnReports.com
    7. Trimedyne Reports Financial Results For The Quarter And Fiscal Year Ended September 30, 2012
    8. Monoclonal Antibody Industry 2013 Global and China Market Analysis in New Research Report at RnRMarketResearch.com
    9. Perrigo Reports Record Second Quarter Revenue, Adjusted Earnings and Operating Cash Flow
    10. Wound and Tissue Management Market in Brazil: Abridged Competitive Analysis, Partial Numerical Data, CAGRs And Qualitative Synopses in New Research Report at ReportsnReports.com
    11. Abaxis Reports Record Revenues For The Third Quarter Of Fiscal 2013
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/25/2016)... , Germany and ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt Prime ... a licensing and co-development agreement with Therawis Diagnostics GmbH to ... will be to develop and market PITX2 as a marker ... other high-risk breast cancer patients. "We are pleased ...
    (Date:5/25/2016)... 2016 According to market research ... and Demand Forecast to 2022 - Industry Insights by ... published by P&S Market Research, the global insulin delivery ... and it is expected to grow at a CAGR ... pump segment is expected to witness the fastest growth ...
    (Date:5/25/2016)... Texas , May 25, 2016 ... the issuance to it by the US Patent ... The company,s technology includes proprietary processes for electronic ... for health and wellness programs, HIPAA compliance and ... "Our technology ...
    Breaking Medicine Technology:
    (Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... According to ... In an industry filled with chemical-laden beauty products, one company is going against the ... for you: Mad Hippie. The rising star in the green space is proud to ...
    (Date:5/26/2016)... Lake MN (PRWEB) , ... May 26, 2016 , ... ... Stance Angle chair , furniture that may support women during pregnancy. Potential benefits ... legs and feet, improved rest and comfort and healthier levels of sitting and standing. ...
    (Date:5/25/2016)... (PRWEB) , ... May 26, 2016 , ... The United ... treatment of androgenetic alopecia in both men and women. To date, the company is ... with FDA clearance for any adult who suffers with androgenetic alopecia. , “This ...
    (Date:5/25/2016)... ... May 25, 2016 , ... “We ... Managing Partner at HealthScape Advisors. “Brad brings significant experience advising healthcare provider clients ... system accelerates with the implementation of MACRA, we believe that continuing to add ...
    (Date:5/25/2016)... Kansas City, MO (PRWEB) , ... May 25, 2016 , ... ... professional, collegiate, and amateur athletics, The National Center for Drug Free Sport (Drug Free ... Drug Free Sport”. This conference, to be held July 12 – 13 in Kansas ...
    Breaking Medicine News(10 mins):